Therefore, we recommend targeting the central pathway by blockade of IL-6 (tocilizumab), IL-1β [canakinumab (IL-1β monoclonal antibody), anakinra (IL-1 receptor antagonist)], and TNF-α (etanercept, infliximab) to control the cytokine storm in the acute phase of COVID-19, thereby reducing cardiovascular impairment and even mitigating MODS. This evidence concerns the gene IL6 and COVID-19.